MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.
暂无分享,去创建一个
C. Berking | A. Hauschild | D. Schadendorf | P. Ascierto | R. Dummer | Simon Wandel | C. Blank | P. Queirolo | M. Peters | A. Zubel | C. V. van Herpen | S. Agarwala | J. Beck | F. Niazi | A. St-Pierre